Metraipolis › archive › dc_91db05c91d64
Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42583162
- DOI
- 10.7759/cureus.112523
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-18T07:57:57.820Z
- SHA-256 of the archived text
375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983- Stable URL of this page
https://metraipolis.com/documento/dc_91db05c91d64
How to cite
Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162 — Europe PMC (en), https://europepmc.org/article/MED/42583162 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_91db05c91d64 (Metraipolis archive dc_91db05c91d64, sha256 375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983)
BibTeX
@misc{dc91db05c91d64,
title = {Effectiveness and Safety of Combined Semaglutide and Dapagliflozin Therapy in Type 2 Diabetes: A Retrospective Cohort Study — Europe PMC PMID:42583162},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42583162},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_91db05c91d64; sha256 375dbadb98ddd0995adfd8836c049d2abe85ef290ec00da118a2d43c1ad55983},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42583162. Agents can read the archived copy with the MCP tool read_document.